Novartis Further Restricts Access To Zelnorm
This article was originally published in The Pink Sheet Daily
Executive Summary
Irritable bowel syndrome therapy available in U.S. only for emergencies.
You may also be interested in...
Ironwood Poised To Move Linaclotide To Phase III In IBS-C
Partnered in the U.S. with Forest, firm formerly known as Microbia seeks to join Amitiza in space vacated by Zelnorm.
Ironwood Poised To Move Linaclotide To Phase III In IBS-C
Partnered in the U.S. with Forest, firm formerly known as Microbia seeks to join Amitiza in space vacated by Zelnorm.
Ironwood Poised To Move Linaclotide To Phase III In IBS-C
With a pair of pivotal Phase III trials in chronic constipation under way, Ironwood Pharmaceuticals reported success Oct. 7 in Phase IIb testing of linaclotide in constipation-predominant irritable bowel syndrome. Partnered in the U.S. with Forest Laboratories, the firm plans to begin two pivotal Phase III trials in IBS-C by next January